The hypoactive sexual desire disorder treatment market is set to expand at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027. Hypoactive sexual desire disorder (HSDD) can be primary, secondary, lifelong or situational; currently physicians worldwide are employing either psychotherapy or pharmacotherapy for its treatment. Recent approval of Bremelanotide (Vyleesi) will propel the HSDD market growth in the near future. Currently 2 drugs such as Prasterone 6.5 mg vaginal insert and BP101 are under phase 3 clinical trial being investigated for its safety and efficacy for treating HSDD. 

"Multifunctional serotonin agonist and antagonist pharmacodynamic profile increases the popularity of flibanserin for treating HSDD"

Hypoactive sexual desire disorder (HSDD) is the absence of sexual thoughts and fantasies causing low libido and sex drive in women population worldwide. The neurochemical basis associated with HSDD in not fully understood but low sex desire has been associated with hyperfunctional inhibition and hypofunctional excitation or a combination of both regulated by neuromodulators. Fluctuating sex hormones during menstrual cycle is also a chief contributing factor for the occurrence of HSDD in women population worldwide. The diagnosis of HSDD is challenging and physicians rely on pharmacotherapy and psychotherapy for its treatment. The PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) aids in initial screening of HSDD. Cognitive behavior therapy is opted in patients responding to counseling sessions with sex therapist. In pharmacotherapy antidepressants such as bupropion and buspirone have been used as off label treatment for HSDD in women showing low sex drive associated with anxiety and depression. Testosterone transdermal patches are used as an off label treatment in premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by USFDA for treating HSDD in premenopausal women by decreasing serotonin activity and increasing norepinephrine and dopamine activity simultaneously.

"Increasing stress and fluctuating hormones are responsible for low sex drive in women population in North America region"

North America holding a share of 38.5% is currently the clear leader in the regional segment for hypoactive sexual desire disorder (HSDD) treatment market. The chief contributing factors for the growing incidence of low sex drive in the women population in the North America region are increasing stress in daily life and fluctuating hormones associated with menstrual cycle. Presence of pharmaceutical companies engaged in the drug development for treating HSDD such as Allergan, Plc., AMAG Pharmaceuticals, S1 Biopharma, Inc., Sprout Pharmaceuticals, Inc etc. further bolster the market growth in the region. Europe accounts for 32.4% market share owing to favorable reimbursement scenario for drugs prescribed for the treatment of HSDD. Asia Pacific represents 15.2% market share and is ready to register faster growth during the forecast period primarily due to rising incidence of stress in working women population and developing healthcare infrastructure.

Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceutcials, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc. and Sprout Pharmaceutcials, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hypoactive Sexual Desire Disorder (HSDD) Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Hypoactive Sexual Desire Disorder (HSDD) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Hypoactive Sexual Desire Disorder (HSDD) Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Hypoactive Sexual Desire Disorder (HSDD) Treatment market?
• Which is the largest regional market for Hypoactive Sexual Desire Disorder (HSDD) Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Hypoactive Sexual Desire Disorder (HSDD) Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Hypoactive Sexual Desire Disorder (HSDD) Treatment market worldwide?